MYHEP LVIR contains two antiviral agents with different mechanisms of action. The combination targets different stages of the HCV life cycle.
How it works:
Who may be prescribed this medicine:
Treatment should not be selected independently. Before therapy, the healthcare provider should evaluate HCV genotype, liver status, previous treatment history, and potential drug interactions.
Research and clinical evidence
Ledipasvir/sofosbuvir has been extensively evaluated in clinical trials and was one of the first fixed-dose direct-acting antiviral combinations to substantially simplify chronic HCV treatment. AASLD notes that direct-acting antiviral therapy has produced very high HCV eradication rates, while ledipasvir/sofosbuvir has its principal role in genotypes 1, 4, 5, and 6.
In genotype 4 studies, the sustained virologic response 12 weeks after treatment (SVR12) was 93% (41/44 patients) in Study 1119 and 100% in the small ION-4 group of 8 patients. In genotype 5 patients in Study 1119, SVR12 was 93% (38/41), while in genotype 6 patients in ELECTRON-2 it was 96% (24/25). Some of these populations were small, so the results should be interpreted with consideration of the limited sample sizes.
Pangenotypic HCV treatment regimens are also available today. Therefore, the decision to use ledipasvir/sofosbuvir should be based on the patient's specific clinical circumstances rather than product availability alone.
MYHEP LVIR is used for the treatment of chronic hepatitis C virus infection. The combination is particularly used in treatment regimens for HCV genotypes 1, 4, 5, and 6.
The primary goal of treatment is to suppress viral replication and achieve a sustained virologic response, meaning that HCV RNA remains undetectable after the appropriate post-treatment assessment period.
Before treatment, the physician evaluates HCV genotype, liver fibrosis/cirrhosis, previous treatment history, hepatic and renal function, HIV or HBV coinfection, and potential drug interactions. Patients should also be tested for current or previous hepatitis B infection because HBV reactivation can occur during HCV antiviral treatment.
The medicine is taken orally once daily at the dose prescribed by the physician, with or without food. The tablet should be swallowed whole and should not be chewed or crushed. Treatment duration is determined by the physician based on HCV genotype, cirrhosis status, previous treatment, and other clinical factors. The dose should not be changed and treatment should not be discontinued without medical advice.
Side Effects
